St. Jude Medical (STJ) Receives Approval for Penta Lead from Japanese MHLW
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Join SI Premium – FREE
St. Jude Medical, Inc. (NYSE: STJ), received regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) of the Penta surgical lead for neurostimulation therapy to manage chronic pain.
The Penta surgical lead addresses complex pain patterns like low back pain and arm and leg pain. Arranged in five columns, the lead is designed to selectively stimulate nerve fibers associated with the patient’s area of pain without affecting other areas. The Penta lead features a proprietary micro-texturing process that enables greater amounts of current to be delivered via the small electrodes.
The Penta surgical lead addresses complex pain patterns like low back pain and arm and leg pain. Arranged in five columns, the lead is designed to selectively stimulate nerve fibers associated with the patient’s area of pain without affecting other areas. The Penta lead features a proprietary micro-texturing process that enables greater amounts of current to be delivered via the small electrodes.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Saba Capital funds reapprove merger plan targeting Q4 2026 close
- Provident Financial prices $175M subordinated notes at 6.50%
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
